The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, California, from August 25-27. This meeting brought together leading experts in the field of multiple myeloma to discuss and present preclinical and clinical data, as well as novel approaches in the treatment and diagnosis of myeloma.
It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609
📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:
Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?
The 19th International Myeloma Society Annual Meeting
25–27 August 2022 | Los Angeles, California
The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, California, from August 25-27. This meeting brought together leading experts in the field of multiple myeloma to discuss and present preclinical and clinical data, as well as novel approaches in the treatment and diagnosis of myeloma.
It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609
📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:
Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?